Parasite macromolecules in Plasmodium-infected erythrocytes

Parasite macromolecules in Plasmodium-infected erythrocytes refers to the collective set of biological polymers—including proteins, nucleic acids, and lipids—synthesized by Plasmodium species during their asexual reproductive stage within human red blood cells [1]. These macromolecules are essential for the parasite's survival, growth, and evasion of the host immune system [2]. Key processes involving these molecules include the degradation of host hemoglobin, the detoxification of released heme into hemozoin, and the transport of nutrients across the parasitophorous vacuolar membrane [3]. Many classic and modern antimalarial drugs exert their effects by binding to or disrupting these macromolecules, such as quinolines interfering with heme polymerization or artemisinins causing widespread oxidative damage to parasite proteins [4]. Because this term encompasses a vast array of distinct molecular entities, it is typically used as a general classification for drugs whose specific molecular receptor is either multi-factorial or not fully characterized within the infected erythrocyte environment [5]. In drug discovery databases like ChEMBL, this designation often groups compounds that show phenotypic activity against the intra-erythrocytic parasite without a confirmed single-protein target [6]. Understanding these interactions is critical for addressing the challenge of multi-drug resistance, which often arises from mutations in the genes encoding these macromolecules [7]. Consequently, this target category represents the primary interface for therapeutic intervention in clinical malaria [8].

Other names

Plasmodium macromoleculesIntra-erythrocytic parasite targetsMalarial parasite proteinsParasite macromolecules

Inhibition of heme biocrystallization, induction of oxidative stress, inhibition of dihydrofolate reductase, and disruption of mitochondrial electron transport [3, 4].